NYSE · PHARMACEUTICAL PREPARATIONS · SMALL CAP
Rafael Holdings, Inc. RFL
10 fiscal years on record · USD · FY2025 reported
SEC FILINGS ONLY
Revenue · FY2025
$30,000
▼ 95.3% vs FY2024
EPS · FY25
—
Dividend / sh · FY25
—
Payout · FY25
—
ROE · FY25
-34.6%
Net margin · FY25
-101733.3%
Dividend coverage
—
Advertisement
AdSense · Leaderboard 728×90320×100
Result
USD 30,000.00
Revenue, FY2025 · full 10-year series below
Revenue
Net income
The company lost 101733 cents on every revenue dollar this year.
Per share
—
Diluted EPS, FY2025
EPS
The company pays no cash dividend.
Profitability
-34.6%
Return on equity, FY2025
ROE
Operating margin-97196.7%
Net margin-101733.3%
Return on assets-28.9%
Each USD of equity lost 35 cents this year.
Returned to shareholders
—
returned in FY2025 · dividends + net buybacks
Dividends paid—
Net buybacks—
Share of profit—
Consecutive raises—
Growth
−63.9% a year
revenue, compounded over five years
CAGR
3 yrs
5 yrs
10 yrs
15 yrs
Revenue
−58.2%
−63.9%
Compound annual rates per period — left blank where the series crosses a loss.
Share base
—
Shares outstanding, FY2025
Change, 5 years—
Change, 10 years—
A share split breaks the comparison across the period, so we leave it out.
Advertisement
AdSense · Leaderboard 728×90300×250
Balance sheet
USD 114.1M
total assets, end of FY2025
Total assetsUSD 114.1M
EquityUSD 94.4M
CashUSD 52.8M
Current ratio4.89×
Equity funds 83% of total assets.
History
10 fiscal years
Every figure from documents filed with the SEC · USD
Metric
2025
2024
2023
2022
2021
2020
2019
2018
2017
2016
Revenue $B
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
Operating income $B
−0.0
−0.1
−0.0
−0.1
−0.0
−0.0
−0.0
−0.0
0.0
0.0
EBITDA $B
·
·
−0.0
−0.1
−0.0
−0.0
−0.0
−0.0
0.0
0.0
Income tax $B
−0.0
−0.0
−0.0
·
0.0
0.0
−0.0
0.0
0.0
0.0
Net income $B
−0.0
−0.0
−0.0
−0.1
−0.0
−0.0
−0.0
−0.0
0.0
0.0
EPS, diluted $
·
·
·
·
·
·
·
·
·
·
Dividend / sh $
·
·
·
·
·
·
·
·
·
·
Payout %
·
·
·
·
·
·
·
·
·
·
ROE %
−34.6
−37.7
−1.9
−111.9
−19.3
−9.4
−4.3
−14.6
0.3
·
Shares out B
·
·
·
·
·
·
·
·
·
·
Slide the table for earlier years · "·" marks figures not disclosed in the filing for that year.
How we verifyAUDITED
28 of 28
checks passed before publication
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidity
Every figure was compared against the original statement: 0 failures and 0 presentation gaps.
What we don’t show
We’d rather say what’s missing than fill the gap with an estimate.
P/E rationeeds a market quote — not yet licensed
Market capitalizationneeds a market quote — not yet licensed
Dividend yieldneeds a market quote — not yet licensed
Price-to-bookneeds a market quote — not yet licensed